Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.

CONCLUSIONS: Demcizumab in combination with paclitaxel has a manageable toxicity profile and showed activity in patients with heavily pretreated platinum-resistant ovarian cancer. PMID: 32037195 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32037195?dopt=Abstract

Source: Gynecologic Oncology - February 5, 2020 Category: Cancer & Oncology Authors: Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN Tags: Gynecol Oncol Source Type: research